1. Select amino acids recover cytokine-altered ENaC function in human bronchial epithelial cells.
- Author
-
Sasidharan A, Grosche A, Xu X, Kinane TB, Angoli D, and Vidyasagar S
- Subjects
- Humans, Th2 Cells immunology, Th2 Cells metabolism, Th2 Cells drug effects, Tumor Necrosis Factor-alpha metabolism, Cell Line, Th1 Cells immunology, Th1 Cells drug effects, Th1 Cells metabolism, Interleukin-13 metabolism, Epithelial Sodium Channels metabolism, Epithelial Sodium Channels genetics, Bronchi cytology, Bronchi metabolism, Bronchi drug effects, Epithelial Cells metabolism, Epithelial Cells drug effects, Cytokines metabolism, Amino Acids pharmacology
- Abstract
The airway epithelium plays a pivotal role in regulating mucosal immunity and inflammation. Epithelial barrier function, homeostasis of luminal fluid, and mucociliary clearance are major components of mucosal defense mechanisms. The epithelial sodium channel (ENaC) is one of the key players in controlling airway fluid volume and composition, and characteristic cytokines cause ENaC and barrier dysfunctions following pulmonary infections or allergic reactions. Given the limited understanding of the requisite duration and magnitude of cytokines to affect ENaC and barrier function, available treatment options for restoring normal ENaC activity are limited. Previous studies have demonstrated that distinct amino acids can modulate epithelial ion channel activities and barrier function in intestines and airways. Here, we have investigated the time- and concentration-dependent effect of representative cytokines for Th1- (IFN-γ and TNF-α), Th2- (IL-4 and IL-13), and Treg-mediated (TGF-β1) immune responses on ENaC activity and barrier function in human bronchial epithelial cells. When cells were exposed to Th1 and Treg cytokines, ENaC activity decreased gradually while barrier function remained largely unaffected. In contrast, Th2 cytokines had an immediate and profound inhibitory effect on ENaC activity that was subsequently followed by epithelial barrier disruption. These functional changes were associated with decreased membrane protein expression of α-, β-, and γ-ENaC, and decreased mRNA levels of β- and γ-ENaC. A proprietary blend of amino acids was developed based on their ability to prevent Th2 cytokine-induced ENaC dysfunction. Exposure to the select amino acids reversed the inhibitory effect of IL-13 on ENaC activity by increasing mRNA levels of β- and γ-ENaC, and protein expression of γ-ENaC. This study indicates the beneficial effect of select amino acids on ENaC activity in an in vitro setting of Th2-mediated inflammation suggesting these amino acids as a novel therapeutic approach for correcting this condition., Competing Interests: Sadasivan Vidyasagar shares and royalties in Entrinsic Bioscience Inc.. A patent application was files with Sadasivan Vidyasagar, Anusree Sasidharan, Astrid Grosche as contributing inventors. This does not alter our adherence to PLOS ONE policies on sharing data and materials., (Copyright: © 2024 Sasidharan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF